DPP4 Substrate Supplementation Protects From WNT‐Induced Lipid Depletion in Dermal Adipocytes
- 26 August 2026
- journal article
- research article
- Published by Wiley in Experimental Dermatology
- Vol. 35 (9) , e70354
Abstract
Adipocytes exhibit remarkable plasticity, dynamically gaining and losing lipid content. However, during skin fibrosis, this adaptability becomes detrimental as adipocytes undergo lipid depletion associated with disease pathology. We previously identified the WNT signalling pathway—acting through Dipeptidyl Peptidase IV (DPP4) – as a key mediator of lipid depletion associated with skin fibrosis, but the mechanism remains unclear. DPP4 is an exopeptidase that cleaves a wide array of substrates across different cell types. Here, we investigate whether modulation of lipid‐regulating DPP4 substrates is sufficient to preserve lipid content in WNT‐activated dermal adipocytes. Using two complementary strategies, we found that supplementation with the DPP4 substrates Neuropeptide Y (NPY) and Glucose‐dependent Insulinotropic Peptide (GIP) can partially protect lipid content in dermal adipocytes. When used in combination, we found that the protection against lipid depletion was more effective than monotherapy alone. These findings demonstrate that supplementation with DPP4 substrates provides a basis for targeted treatments for lipodystrophy syndromes and skin fibrosis.Keywords
Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR076938)
- National Scleroderma Foundation
This publication has 38 references indexed in Scilit:
- Lipodystrophy and adipose tissue recovery are mediated by the Wnt/lipogenesis axis during skin fibrosisThe Journal of Pathology, 2026
- Neprilysin-dependent neuropeptide Y cleavage in the liver promotes fibrosis by blocking NPY-receptor 1Cell Reports, 2023
- Adipocyte plasticity in tissue regeneration, repair, and diseaseCurrent Opinion in Genetics & Development, 2022
- Vildagliptin, a CD26/DPP4 inhibitor, ameliorates bleomycin-induced pulmonary fibrosis via regulating the extracellular matrixInternational Immunopharmacology, 2020
- Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic SclerosisArthritis & Rheumatology, 2019
- Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in SkinJournal of Investigative Dermatology, 2018
- Inhibition of β-Catenin Signaling in the Skin Rescues Cutaneous Adipogenesis in Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial of C-82Journal of Investigative Dermatology, 2017
- Myofibroblasts in Murine Cutaneous Fibrosis Originate From Adiponectin‐Positive Intradermal ProgenitorsArthritis & Rheumatology, 2014
- DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trialsDiabetes & Metabolism, 2012
- A Small‐Molecule Agonist of the Wnt Signaling PathwayAngewandte Chemie International Edition, 2005